InsidersTradesSigma
Track the ORASURE TECHNOLOGIES INC stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ORASURE TECHNOLOGIES INC has logged 69 reports. Market capitalisation: €261.6m. The latest transaction was reported on 30 June 2026 (Attribution). Among the most active insiders: Datin James A. The full history is openly available.
69
Insider Decl.
n/a
Thresholds
€345,816
6 ops.
Buy Volume
n/a
n/a
Sell Volume
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,250 of 29,062 companies
17.5
score / 100
Value9
Quality26
FCF yld-21%
Earn yld-28%
EV/EBITDA·
ROE-14%
Gross mgn42%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 June 2026
Declarations69 total
3,666 sharesCommon StockSEC:0001470831-26-000683:0
46,106 shares0Common StockSEC:0001470831-26-000516:0
46,106 shares0Common StockSEC:0001470831-26-000515:0
22,888 shares@ US$3.020.029% mcap100.0% of flowCommon StockSEC:0001470831-26-000437:0
28,406 shares@ US$3.020.035% mcap26.3% of flowCommon StockSEC:0001470831-26-000438:0
25,000 shares@ US$2.980.031% mcap100.0% of flowCommon StockSEC:0001470831-26-000443:0
Canonical exit: 10 Aug 2026 (T+90)
21,305 shares@ US$3.020.027% mcap34.9% of flowCommon StockSEC:0001470831-26-000436:0
33,661 shares0Common StockSEC:0001470831-26-000442:0
5,246 shares@ US$3.097518.1% of flowCommon StockSEC:0001116463-26-000019:0
32,300 shares@ US$2.9288100.0% of flowCommon StockSEC:0001470831-26-000311:0
Canonical exit: 18 Jun 2026 (T+90)
32,300 shares@ US$2.92872.1% of flowCommon StockSEC:0001470831-26-000310:0
Canonical exit: 18 Jun 2026 (T+90)
14,183 shares0Common StockSEC:0001470831-26-000294:0
22,021 shares@ US$2.998533.9% of flowCommon StockSEC:0001470831-26-000282:0
Canonical exit: 11 Jun 2026 (T+90)
22,022 shares@ US$2.99851.5% of flowCommon StockSEC:0001470831-26-000281:0
Canonical exit: 11 Jun 2026 (T+90)
26,814 shares0Common StockSEC:0001470831-26-000242:0
129,032 shares0Common StockSEC:0001470831-26-000241:0
10,286 shares@ US$2.4638.6% of flowCommon StockSEC:0001470831-25-000448:0
34,632 shares0Common StockSEC:0001470831-25-000380:0
2,100 shares@ US$2.37232.7% of flowCommon StockSEC:0001470831-25-000377:0
Canonical exit: 26 Feb 2026 (T+90)
6,118 shares@ US$3.26949.7% of flowCommon StockSEC:0001470831-25-000232:0
12,524 shares@ US$2.7826.7% of flowCommon StockSEC:0001062993-25-014059:0
7,317 shares@ US$3.20525.8% of flowCommon StockSEC:0001062993-25-013517:0
6,657 shares@ US$3.0082100.0% of flowCommon StockSEC:0001062993-25-012140:0
335,710 shares0Common StockSEC:0001062993-25-011071:0
5,623 shares@ US$2.89010.0074% mcap6.5% of flowCommon StockSEC:0001062993-22-015567:0
25 of 69 declarations
关于 ORASURE TECHNOLOGIES INC
OraSure Technologies Inc.（股票代码：OSUR）是一家总部位于美国的医疗保健诊断公司，在美国纳斯达克上市。对于法语投资者而言，其股票故事位于即时诊断、家庭检测以及样本采集/稳定技术之间。该公司于1987年在宾夕法尼亚州伯利恒成立，名为SolarCare，并于2000年进入公开市场后更名为OraSure Technologies。其悠久的运营历史和监管专业知识是其核心投资吸引力的一部分。（[orasure.com](https://orasure.com/company.html)） OraSure的业务大致围绕两大支柱展开。首先，它开发和商业化快速诊断测试，其中OraQuick平台是最知名的特许经营权。这些产品历史上涵盖了传染病筛查，如HIV、丙型肝炎和梅毒，以及其他关键疾病和公共卫生应用。其次，该公司销售用于分子诊断、基因组学研究、微生物组研究和制药工作流程的样本采集和稳定解决方案。其产品组合旨在支持多种样本类型，包括唾液、口腔液、尿液、皮肤细胞、血液和粪便。这种组合使OraSure相对于纯粹的诊断同行具有差异化的地位。（[orasure.com](https://orasure.com/company.html)） 从竞争角度来看，OraSure是一个利基市场参与者，而非一个广泛多元化的医疗技术平台。其优势包括在自检和即时诊断方面的深厚传承、在某些传染病类别中的知名品牌以及互补的样本管理特许经营权。与此同时，该公司仍然面临公共卫生资金需求波动、检测算法或报销条件变化、产品采用周期以及来自更新或成本更低技术的竞争。管理层强调监管执行、产品创新和商业渠道扩张是未来增长的关键杠杆。（[orasure.gcs-web.com](https://orasure.gcs-web.com/news-releases/news-release-details/orasure-announces-fourth-quarter-2025-financial-results?utm_source=openai)） 近期发展对股票投资者至关重要。2026年2月，OraSure表示预计2026年将恢复增长，这得益于计划推出的衣原体和淋病快速分子自检产品以及用于性传播感染（STI）应用的Colli-Pee™家用尿液采集设备。2025年3月，董事会批准了一项为期24个月、由手头现金资助的40 million美元股票回购计划，这表明了对资产负债表和资本配置纪律的信心。该公司还提到了2025年的运营重置以及为稳定需求和实现客户群多元化而持续进行的努力。简而言之，OSUR是一家在纳斯达克上市的美国医疗保健公司，拥有专注的诊断特许经营权、经常性的监管催化剂和显著的执行风险。（[orasure.gcs-web.com](https://orasure.gcs-web.com/news-releases/news-release-details/orasure-announces-fourth-quarter-2025-financial-results?utm_source=openai)）
